Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to understand the safety of AXT107 injected
suprachoroidally in participants with nAMD. The main question[s] it aims to answer are:
- Safety of the maximum tolerable dose of AXT107
- Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will
be injected with AXT107 and will be followed on a regular monitoring visits through 9
months post single injection.